1309362-02-4

Basic information

• Product Name: C₂₁H₂₂N₂O₅S
• Synonyms: C₂₁H₂₂N₂O₅S
• CAS NO: 1309362-02-4
• Molecular Weight: 414.482
• Mol File: 1309362-02-4.mol

Chemical Properties

• CAS DataBase Reference: C₂₁H₂₂N₂O₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₁H₂₂N₂O₅S(1309362-02-4)
• EPA Substance Registry System: C₂₁H₂₂N₂O₅S(1309362-02-4)

Safety Data

• Hazardous Substances Data: 1309362-02-4(Hazardous Substances Data)

Upstream product

• 70744-03-5 3-amino-4-hydroxy-1-methyl-1H-quinolin-2-one 
• 36949-55-0 4-hydroxy-1-methyl-3-nitro-2-(1H)quinolinone 
• 1677-46-9 4-hydroxy-1-methyl-2(1H)-quinolone 
• 1309362-14-8 C₁₄H₁₆N₂O₃ 
• 98-59-9 p-toluenesulfonyl chloride 

Relevant articles and documents

Synthesis and antikinetoplastid activities of 3-substituted quinolinones derivatives

A new family of quinolinone derivatives has been synthesized and evaluated for their antikinetoplastid activities against Leishmania donovani and Trypanosoma brucei brucei. Results from these structure-activity relationship studies enabled identification of compounds 3a and 4g as the most active compounds against L. donovani promastigotes and amastigotes parasites (IC 50 values in a range of 2-11 μM). Additionally, compound 3b has emerged from this study as the most active compound in the series against T. b. brucei with a MEC value of 12 μM. These three compounds are worth of further in vivo evaluation.

Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery

Heat shock protein90 (Hsp90) is a significant target in the development of rational cancer therapy, due to its role at the crossroads of multiple signaling pathways associated with cell proliferation and viability. Here, a novel series of Hsp90 inhibitors containing a quinolein-2-one scaffold was synthesized and evaluated in cell proliferation assays. Results from these structure-activity relationships studies enabled identification of the simplified 3-aminoquinolein-2-one analogue 2b (6BrCaQ), which manifests micromolar activity against a panel of cancer cell lines. The molecular signature of Hsp90 inhibition was assessed by depletion of standard known Hsp90 client proteins. Finally, processing and activation of caspases 7, 8, and 9, and the subsequent cleavage of PARP by 6BrCaQ, suggest stimulation of apoptosis through both extrinsic and intrinsic pathways. Hot stuff! A novel series of Hsp90 inhibitors containing a quinolein-2-one scaffold was synthesized and screened in cell proliferation assays. The most potent inhibitor, 6BrCaQ, exhibited strong antiproliferative activity against a panel of cancer cell lines and resulted in downregulation of Hsp90 client proteins. Moreover, 6BrCaQ induced a high level of apoptosis in MCF-7 breast cancer cells, and was found to mediate cell death in a p23-independent manner.